User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT).

  1. Van Steenbergen Werner, Peeters Pascal, De Bondt Joris, Staessen Dirk, Büscher Henri, Laporta Thiery, Roskams Tania, Desmet Valeer, Nimesulide-induced acute hepatitis: evidence from six cases, 10.1016/s0168-8278(98)80188-8
  2. McCormick PA, Kennedy F, Curry M, Traynor O, COX 2 inhibitor and fulminant hepatic failure, 10.1016/s0140-6736(05)74867-4
  3. Schattner A., Sokolovskaya N., Cohen J., Fatal hepatitis and renal failure during treatment with nimesulide, 10.1046/j.1365-2796.2000.00612.x
  4. Weiss P, Mouallem M, Bruck R, Hassin D, Tanay A, Brickman CM, Farfel Z, Bar-Meir S (1999) Nimesulide-induced hepatitis and acute liver failure. Isr Med Assoc J 1:89–91
  5. Andrade Raúl J., Lucena M.Isabel, Fernández M.Carmen, González Mercedes, Letters to the Editor, 10.1016/s0168-8278(00)80208-1
  6. Macia MA, Carvajal A, del Pozo JG, Vera E, del Pino A (2002) Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 72:596–597
  7. Merlani Giorgio, Fox Mark, Oehen Hans-Peter, Cathomas Gieri, Renner Eberhard L., Fattinger Karin, Schneemann Markus, Kullak-Ublick Gerd A., Fatal hepatotoxicity secondary to nimesulide, 10.1007/s002280100312
  8. (2007) Nimesulide withdrawal too little, too late? Irish Pharmacy J85
  9. Finish Medicines Agency (2002) The sale of Nimed, an anti-inflammatory analgesic, is temporarily suspended due to its adverse liver effects. Available at: http://www.fimea.fi/whats_new/1/0/the_sale_of_nimed_an_anti-inflammatory_analgesic_is_temporarily_suspended_due_to_its_adverse_liver_effects
  10. Irish Medicines Board (IMB) (2007) IMB announces immediate suspension of the marketing of medicines containing nimesulide. IRB, Dublin
  11. World Health Organization (WHO) (2007). Oral nimesulide: marketing suspended in Ireland due to reports of liver failure. WHO Information Exchange System Alert No 113 (23 May 2007). WHO, Geneva
  12. European Medicines Agency (EMEA) (2004) Committee for proprietary medicinal products opinion following an article 31 referral. Nimesulide-containing products. EMEA Press Office, London
  13. European Medicines Agency (EMEA) (2007) European Medicines Agency recommends restricted use of nimesulide-containing medicinal products. EMEA Press Office, London
  14. European Medicines Agency (EMEA) (2007) Questions and answers on the CHMP recommendation on nimesulide-containing medicines. EMEA Agency Press Office, London
  15. Lapeyre-Mestre Maryse, de Castro Ana Maria Rueda, Bareille Marie-Pierre, Pozo Javier Garcia del, Requejo Ana Alvarez, Arias Louis Martin, Montastruc Jean-Louis, Carvajal Alfonso, Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems, 10.1111/j.1472-8206.2006.00416.x
  16. Lee Chang-Hsing, Wang Jung-Der, Chen Pau-Chung, Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs, 10.1002/pds.1966
  17. Traversa G., Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs, 10.1136/bmj.327.7405.18
  18. Théophile Hélène, Laporte Joan-Ramon, Moore Nicholas, Martin Karin-Latry, Bégaud Bernard, The Case-Population Study Design : An Analysis of its Application in Pharmacovigilance, 10.2165/11592140-000000000-00000
  19. Benichou Christian, Danan Gaby, Flahault Antoine, Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge, 10.1016/0895-4356(93)90102-7
  20. Danan Gaby, Benichou Christian, Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries, 10.1016/0895-4356(93)90101-6
  21. Edwards I. Ralph, Biriell Cecilia, Harmonisation in Pharmacovigilance : , 10.2165/00002018-199410020-00001
  22. Macedo A. F., Marques F. B., Ribeiro C. F., Teixeira F., Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability, 10.1046/j.1365-2710.2003.00475.x
  23. Meyboom Ronald H.B., Hekster Yechiel A., Egberts Antoine C.G., Gribnau Frank W.J., Edwards I. Ralph, Causal or Casual? : The Role of Causality Assessment in Pharmacovigilance, 10.2165/00002018-199717060-00004
  24. Methodology W.C.C.f.D.S (2010) Guidelines for ATC classification and DDD assignment 2011. WHO Collaborating Centre for Drug Statistics Methodology, Oslo
  25. Arimone Yannick, Bégaud Bernard, Miremont-Salamé Ghada, Fourrier-Réglat Annie, Molimard Mathieu, Moore Nicholas, Haramburu Françoise, A new method for assessing drug causation provided agreement with experts' judgment, 10.1016/j.jclinepi.2005.08.012
  26. Arimone Yannick, Bégaud Bernard, Miremont-Salamé Ghada, Fourrier-Réglat Annie, Moore Nicholas, Molimard Mathieu, Haramburu Françoise, Agreement of expert judgment in causality assessment of adverse drug reactions, 10.1007/s00228-004-0869-2
  27. Arimone Yannick, Miremont-Salamé Ghada, Haramburu Françoise, Molimard Mathieu, Moore Nicholas, Fourrier-Réglat Annie, Bégaud Bernard, Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions, 10.1111/j.1365-2125.2007.02937.x
  28. Théophile Hélène, Arimone Yannick, Miremont-Salamé Ghada, Moore Nicholas, Fourrier-Réglat Annie, Haramburu Françoise, Bégaud Bernard, Comparison of Three Methods (Consensual Expert Judgement, Algorithmic and Probabilistic Approaches) of Causality Assessment of Adverse Drug Reactions : An Assessment Using Reports Made to a French Pharmacovigilance Centre, 10.2165/11537780-000000000-00000
  29. Gülmez Sinem Ezgi, Lignot-Maleyran Séverine, de Vries Corinne S., Sturkenboom Miriam, Micon Sophie, Hamoud Fatima, Blin Patrick, Moore Nicholas, Administrative complexities for a European observational study despite directives harmonising requirements : EUROPEAN HARMONISATION, 10.1002/pds.3204
  30. Sánchez-Fueyo Alberto, Hot-topic debate on tolerance: Immunosuppression withdrawal, 10.1002/lt.22421
  31. Tsochatzis E., Koskinas J., Manesis E.K., Archimandritis A.J., Liver Transplantation in Greek Patients: Epidemiological Data, Morbidity, and Mortality of 71 Patients from a Single Center With 6 Years of Mean Follow-up, 10.1016/j.transproceed.2006.11.010
  32. Criteria of drug-induced liver disorders, 10.1016/0168-8278(90)90124-a
  33. MIMS Publications (July 2007). IMB suspension of marketing of nimesulide containing medicines. IMB Notice Information: Human Medicines
Bibliographic reference Gulmez, Sinem Ezgi ; Larrey, Dominique ; Pageaux, Georges-Philippe ; Lignot-Maleyran, Séverine ; de Vries, Corinne ; et. al. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT).. In: European Journal of Clinical Pharmacology, Vol. 69, no. 3, p. 605-616 (2013)
Permanent URL http://hdl.handle.net/2078.1/117086